{
  "label": "clinical_signal_03_dx_vaccine_immunogenicity_023",
  "artifact_type": "distractor_episode",
  "artifact_id": "sha256:b5b24c20ef02772b2081d28de037a677ea044d844c5a04d72ddb33e512033b4d",
  "input_ids": [
    "sha256:b4ba5337b06c8de68ac3315db1a4f6980c5bd48efd529c3914f30297d6afd329",
    "sha256:b9a5f4498416bfb2148e106e9d25ca838481bb56025a18e16baf31718f4ee4a2"
  ],
  "prompt_id": null,
  "model_config": null,
  "created_at": "2026-02-17T12:01:18.084691",
  "content": "## 2024-08-05 Daily Operations Summary\n\n### Enrollment\n- Total Enrolled: 127\n- Active: 119\n- Screen Failures Cumulative: 30\n- Withdrawals Cumulative: 8\n\n#### By Dose Group\n- Low Dose: 29\n- Mid Dose: 32\n- High Dose: 32\n- Placebo: 34\n\n### Immunogenicity By Group\n#### Low Dose\n- IgG Titer (GMU) Mean: 62.1\n- IgG Titer (GMU) SD: 6.0\n- IgM Titer (GMU) Mean: 18.8\n- IgM Titer (GMU) SD: 4.0\n- Neutralizing Ab ID50 Mean: 99.1\n- Neutralizing Ab ID50 SD: 10.0\n- CD4 Response (SFC per 10^6) Mean: 143.0\n- CD4 Response (SFC per 10^6) SD: 15.0\n- CD8 Response (SFC per 10^6) Mean: 106.0\n- CD8 Response (SFC per 10^6) SD: 11.0\n- Seroconversion Percentage: 22.2\n\n#### Mid Dose\n- IgG Titer (GMU) Mean: 90.7\n- IgG Titer (GMU) SD: 9.6\n- IgM Titer (GMU) Mean: 29.3\n- IgM Titer (GMU) SD: 6.4\n- Neutralizing Ab ID50 Mean: 152.4\n- Neutralizing Ab ID50 SD: 16.0\n- CD4 Response (SFC per 10^6) Mean: 223.0\n- CD4 Response (SFC per 10^6) SD: 24.0\n- CD8 Response (SFC per 10^6) Mean: 166.0\n- CD8 Response (SFC per 10^6) SD: 18.0\n- Seroconversion Percentage: 34.8\n\n#### High Dose\n- IgG Titer (GMU) Mean: 124.8\n- IgG Titer (GMU) SD: 13.2\n- IgM Titer (GMU) Mean: 40.0\n- IgM Titer (GMU) SD: 8.8\n- Neutralizing Ab ID50 Mean: 196.6\n- Neutralizing Ab ID50 SD: 22.0\n- CD4 Response (SFC per 10^6) Mean: 316.0\n- CD4 Response (SFC per 10^6) SD: 33.0\n- CD8 Response (SFC per 10^6) Mean: 215.0\n- CD8 Response (SFC per 10^6) SD: 24.0\n- Seroconversion Percentage: 49.5\n\n#### Placebo\n- IgG Titer (GMU) Mean: 15.7\n- IgG Titer (GMU) SD: 1.2\n- IgM Titer (GMU) Mean: 1.3\n- IgM Titer (GMU) SD: 0.8\n- Neutralizing Ab ID50 Mean: 26.5\n- Neutralizing Ab ID50 SD: 2.0\n- CD4 Response (SFC per 10^6) Mean: 27.0\n- CD4 Response (SFC per 10^6) SD: 3.0\n- CD8 Response (SFC per 10^6) Mean: 18.0\n- CD8 Response (SFC per 10^6) SD: 2.0\n- Seroconversion Percentage: 1.5\n\n### Injection Site Reactions\n- Pain Percentage: 48.5\n- Erythema Percentage: 28.2\n- Swelling Percentage: 15.2\n- Induration Percentage: 8.5\n- Mean Pain Duration (Hours): 16.6\n\n### Systemic Reactogenicity\n- Fever Percentage: 12.7\n- Fatigue Percentage: 37.2\n- Myalgia Percentage: 19.9\n- Headache Percentage: 26.9\n- Chills Percentage: 10.4\n\n### Safety Labs\n- WBC (K) Mean: 5.9\n- WBC (K) SD: 1.3\n- Lymphocyte Percentage Mean: 35.8\n- Lymphocyte Percentage SD: 6.1\n- Neutrophil Percentage Mean: 53.8\n- Neutrophil Percentage SD: 6.6\n- Platelets (K) Mean: 252\n- Platelets (K) SD: 38\n- CRP (mg/L) Mean: 7.2\n- CRP (mg/L) SD: 1.3\n- Hemoglobin (g/dL) Mean: 13.8\n- Hemoglobin (g/dL) SD: 1.1\n\n### Adverse Events\n- AE ID: VI-AE-2361, Description: chills, Grade: 2, Relatedness: possibly related, Resolved: true, Dose Group: mid_dose\n- AE ID: VI-AE-2378, Description: arthralgia, Grade: 1, Relatedness: possibly related, Resolved: true, Dose Group: low_dose\n- AE ID: VI-AE-2331, Description: lymphadenopathy, Grade: 2, Relatedness: related, Resolved: true, Dose Group: low_dose\n\n### Events\n- DSMB safety review teleconference completed\n- Site 03 monitoring visit, 1 minor findings\n- Serum sample aliquoting completed for 20 subjects\n\n### Notes\n- Week 23: Immunogenicity assessments on schedule. 127 subjects enrolled across dose groups. Reactogenicity profiles consistent with prior weeks.",
  "metadata": {
    "episode_type": "distractor",
    "theme": "vaccine_immunogenicity",
    "theme_index": 1,
    "local_index": 23,
    "scope_id": "clinical_signal_03",
    "layer_name": "distractor_episodes",
    "layer_level": 2,
    "build_fingerprint": {
      "scheme": "synix:build:v1",
      "digest": "86d399f4ea18a5663d6624e24cd8b639bcd4c45932ccbdc83c5254419dc5a8df",
      "components": {
        "transform": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
        "inputs": "c06ced136368edaf"
      }
    },
    "transform_fingerprint": {
      "scheme": "synix:transform:v2",
      "digest": "a88665a5359d5ac5d2c858c77a2a19318c209adeea6fae2b838d79e11f6aba2b",
      "components": {
        "transform_id": "01137a4997b78f86",
        "source": "c42d9c6282d5331f",
        "model": "1e2ccf75e96d7ee7"
      }
    }
  }
}